baber/WOPTO huggingface dataset:
Patent FI-940420-A0 (FI)
Inventor: BIETTI GIUSEPPE
IPC: A61K31/505
Filed: 1994-01-28
Abstract: Pharmacologically active benzimidazolone derivatives as 5-HT1A and 5-HT2 receptors, useful in the treatment of CNS disorders of formula:   <CHEM>  wherein R1 and R2 may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 acyl, carboxyl, C1-6 alkoxy- carbonyl, hydroxy, nitro, amino optionally C1-4 alkyl N-mono or di-substituted, C1-6 acylamino, C1-6 alkoxycarbonylamino, carbamoyl optionally C1-4 alkyl N-mono or di-substituted, cyano, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, amino sulphonyl optionally C1-4 alkyl N-mono or di-substituted, C1-4 alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino;     R3 is hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-C6 alkynyl;     A is -CO- or -CONH- or it is absent;     B is a straight or branched, saturated or unsaturated C2-6 alkyl;     m and n are both independently an integer from 1 to 3; R4 is an aryl, aralkyl, a heteroaryl or heteroaralkyl group, each group being optionally substituted by one or more substituents selected from halogen, trifluoromethyl, cyano, C1-3 alkoxy, C1-4 alkyland acid addition salts thereof. The process for the preparation of the compounds of formula I as well as pharmaceutical compositions containing them are also described.
Patent FI-941309-A0 (FI)
Inventor: ELLINGBOE JOHN WATSON
IPC: C07D471/04
Filed: 1994-03-21
Abstract: This invention relates to intermediates useful in the production of substituted pyridopyrimidinones of general formula (I): <CHEM>  wherein     n is 0 to 3; R<1> and R<2> are, independently, H, C1-C6alkyl, hydroxy(C1-C6alkyl), formyl, carbonyl(C1-C6alkyl), carboxy, or carboxy(C1-C6alkyl);   R<3> and R<4> are, independently, H, C1-C6alkyl, or hydroxy; R<3a> and R<4a> are H, or one of -CR<3>R<3a> and -CR<4>R<4a> is a carbonyl group; with the proviso that at least one of the groups R<1> and R<2> must be hydroxy(C1-C6alkyl), formyl, carbonyl(C1-C6alkyl), carboxy, or carboxy(C1-C6alkyl); or one of R<3> and R<4> must be hydroxy; or one of -CR<3>R<3a> and -CR<4>R<4a> must be a carbonyl group; ;   Ar<1> is <CHEM>     wherein W is H, C1-C6alkyl, halogen, hydroxy, or C1-C6alkoxy;   Ar<2> is <CHEM>     wherein X is <CHEM> wherein R<5> is H, CH3, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; or a tautomer of said compound,  or a pharmaceutically acceptable salt of said compound or tautomer. The compounds of Formula I are useful for treating hypertension and congestive heart failure. Also disclosed are pharmaceutical compositions containing compounds of Formula I and a pharmaceutically acceptable carrier and methods for production of the compounds of Formula I. Intermediates for making the pharmaceutical useful compounds are also enclosed.
Patent FI-954841-A0 (FI)
Inventor: LU WEN-CHIN
IPC: A61M5/34
Filed: 1995-10-11
Abstract: A safety syringe includes: a hollow needle assembly (2) having a hollow needle portion (21) detachably coupled to a shank portion (22) embedded in a sleeve portion (12) of a syringe (1) and having a needle head portion (23) formed on a rear portion of the shank portion (22), and a plunger (31) slidably held in the syringe (1) and having a biasing socket (32) recessed in the plunger (31) for engaging the needle head portion (23) of the needle assembly (2) for a coupling of the needle assembly (2) with the plunger ( 31) for a retraction into the syringe (1) for obliquely biasing the needle portion (21) for preventing reprotrusion of the needle (2) outwardly, thereby allowing a variety of needles of different sizes to be replaceably mounted on the shank portion (22) outside the syringe (1) for a convenient mounting of the needle (2) on the syringe (1).
Patent FI-962065-A0 (FI)
Inventor: BEESON KARL W
IPC: G02F1/1335
Filed: 1996-05-15
Abstract: An optical element such as used in an array of such elements is configured as a truncated symmetrical solid structure having light input and output surfaces and sides tapering inwardly from the light input surface to the light output surface. The fraction of the input light which is outputted and the angular distribution of the output light vary as a function of said ratio and the tapering angle. Optimal geometries in terms of viewing angle, contrast and THROUGHPUT are for a ratio of the area of the output surface to the area of the input surface ranging between approximately 0.1 and approximately 0.3, and for tapering angles relative to the axis of the structure ranging between approximately 7.5 and approximately 17.5 degrees.
Patent FI-965078-A0 (FI)
Inventor: RITTER RUDOLF
IPC: H04W88/02
Filed: 1996-12-17
Abstract: The signalization device is permanently installed in a peripheral (4, 9) of the communications network, or provided by a chip card inserted in the latter, with a central control (8) controlling the forwarding of the signalization within the communication network. The signalization is provided by a data communication via which data telegrams are exchanged between at least 2 coupled subscribers, provided as a standardised data set, with an additional identification code, for indicating the authorised services, the identification code is verified by a software filter (12.1, 12.2), associated with the subscriber and with a service centre (10). <IMAGE>
Patent FI-971289-A0 (FI)
Inventor: JOHANSSON SIXTEN
IPC: B65D19/00
Filed: 1997-03-26
Abstract: PCT No. PCT/SE95/01089 Sec. 371 Date Apr. 11, 1997 Sec. 102(e) Date Apr. 11, 1997 PCT Filed Sep. 25, 1995 PCT Pub. No. WO96/11852 PCT Pub. Date Apr. 25, 1996A pallet having a plurality of parallel base beams, and a deck joined to the plurality of parallel base beams. The deck includes a web or sheet of material, which is folded to form a deck surface with a plurality of parallel panels adjoining each other, and a plurality of parallel projections on an underside thereof. Each base beam extends upward to contact the underside of the parallel panels, and includes at least one through-recess having a shape which corresponds to a cross-section of a corresponding one of the plurality of parallel projections. The corresponding parallel projection engages the recess thereby forming the pallet with a plurality of spaces to accommodate lifting forks between the plurality of parallel base beams. Lower surfaces of the plurality of parallel projections form lifting surfaces for the lifting forks.
Patent FI-991029-A0 (FI)
Inventor: KOSKI ILPO
IPC: D21F3/02
Filed: 1999-05-05
Abstract: A press for the dewatering of a fiber web, comprising a roll, a counterpart and and an endless press belt adapted to glide around the counterpart. Into the concave press zone region of the counterpart, a flexible press plate is adapted, anchored to the counterpart at the leading edge of the counterpart, relative to web motion. Beneath the press plate, hydrostatic pressure chambers are provided, separated from each other by means of flexible pressure lines. By individually controlling the pressures of the chambers, the leads and optionally the press plate edges, a desired pressure profile is obtained across the extended pressure zone.
Patent AP-9901541-A0 (AP)
Title: Broad-spectrum delta-endotoxins.
Inventor: MALVAR THOMAS
IPC: C07K16/12
Filed: 1997-11-20
Abstract: Disclosed are novel synthetically-modified b. Thuringiensis chimeric crystal proteins having improved insecticidal activity against colepteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using thses genes and proteins are disclosed as well as methods for the recombinant expression, and thransformation of suitable host cells. Transformed host cells and transgenic plants expressing the modified endotoxin are also aspects of the invention.
Patent IL-90434-A0 (IL)
Title: 9-r-azacyclic erythromycin antibiotics
IPC: A61K31/7042
Filed: 1989-05-28
Abstract: Semisynthetic antibiotics with improved therapeutic properties are disclosed. In particular, 9-R-azacyclic derivatives of erythromycin, its derivatives, and their salts and esters show superior antimicrobial activity compared to other macrolide compounds.
Patent IL-92078-A0 (IL)
Title: Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
IPC: A61K31/435
Filed: 1989-10-22
Abstract: The invention relates to specific bicyclic imidazole compounds such as 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, or pharmaceutically acceptable non-toxic salts thereof, for the treatment of hyperaldosteronism, and to a method of treating hyperaldosteronism using such compounds, as well as to the use of said compounds for the preparation of pharmaceutical compositions for the treatment of hyperaldosteronism.
Patent IL-94036-A0 (IL)
Title: Process for the preparation of alkylphosphonous acid diesters and/or dialkylphosphinous acid esters
IPC: C07F9/48
Filed: 1990-04-06
Abstract: The abovementioned compounds are prepared by reacting trialkyl phosphites with phosphorus trichloride and/or monoalkyl esters of dichlorophosphinous acid at -20 to +100 DEG C followed by immediately reacting the product with alkylmagnesium chloride or alkylmagnesium bromide at -60 to +50 DEG C, followed by removing the desired compounds from the distillate of the volatile compound. This allows dialkyl esters of alkylphosphonous acids and monoalkyl esters of dialkylphosphinous acids to be obtained without complicated and costly purification of intermediates. The phosphorus-containing esters obtained, in turn, are valuable intermediates, for example for the preparation of flameproofing agents and crop protection agents.
Patent SE-8701108-A0 (SE)
Title: Hanteringsanordning
Inventor: ASTRID HAMMARBÄCK
IPC: B66C3/16
Filed: 1987-03-18
Abstract: FOre1iggande uppf inning avser en gripanordn1ng, fOretrOdesvis avsedd fOr att lasta, transportera och lossa massaved och/eller timmerstockar. Uppfinningen kannetecknas av att en knaledsmekanism (4,5) ar kopplad mellan gripklorna (1,2) p5 timse sidor om den gernensamma axeln (3) och att ett kraftalstrande don (7) ar kopplat mellan knatedsmekanismen och ena gripkIon (2).
Patent AU-PP724198-A0 (AU)
Title: Vehicle engine coolant pump housing
IPC: F01P5/10
Filed: 1998-11-23
Abstract: A coolant system for a vehicle engine which may retrofitted if desired, the coolant system including a coolant flow circuit which in part includes passage means through an engine block of the vehicle engine and through a heat exchanger. The coolant system further includes a coolant pump which, when operated, causes coolant flow around the coolant flow circuit, the coolant pump being driven by an electric motor independently of the vehicle engine. The coolant system still further includes a coolant temperature sensor and controller means whereby pulsed voltage levels are supplied to the motor in response to differing coolant temperature levels being sensed by the coolant temperature sensor.
Patent FI-20021344-A0 (FI)
Inventor: KORHONEN REIJO
IPC: E04F15/00
Filed: 2002-07-08
Abstract: A resilient element for suspended flooring and a method for manufacturing a suspended floor. The resilient element (1) constitutes an installation element, the length of which substantially exceeds its width, and it comprises an upper structure (2) and a lower structure (3). Between the structures (2, 3) there are arranged first support means (4), which arrange the upper structure (2) and the lower structure (3) at a first height (H1) from one another. The second support means (5) are arranged on the opposite side of the lower structure (3) with respect to the first support means (4). The second support means (5) arrange the lower structure (3) at a first height (H2) from the structure beneath the structure.
Patent IL-101932-A0 (IL)
Title: Processes for the diastereoselective synthesis of oxathiolane,dioxolane and dithiolane derivatives,and oxathiolane and dioxolane derivatives for use therein
IPC: C07H19/04
Filed: 1992-05-20
Abstract: The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity and intermediates useful in those processes.
Patent IL-102344-A0 (IL)
Title: Method of preventing and treating chemotherapy-induced alopecia
Inventor: JIMENEZ JOAQUIN J
IPC: A61P43/00
Filed: 1992-06-28
Abstract: The present invention relates, in general, to a method of inhibiting alopecia, or hair loss, and, in particular, to a method of inhibiting alopecia induced by chemotherapeutic agents. The invention further relates to a composition suitable for use in such a method. Active agents for use in the above method include proteinaceous growth factors, such as EGF, and/or vitamins D3 or metabolites thereof.
Patent IL-105098-A0 (IL)
Title: Peptidic quinuclidines
IPC: A61P25/00
Filed: 1993-03-18
Abstract: Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of formula (I) and the pharmaceutically-acceptable salts thereof, wherein X<1> is alkoxy or halosubstituted alkoxy; X<2> is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halosubstitued alkyl, halosubstituted alkoxy, alkylamino, dialkylamino, alkylsulfonylamino (which may be substituted), N-alkyl-N-alkylsulfonylamino (which may be substituted), alkanoylamino (which may be substituted) or N-alkyl-N-alkanoylamino (which may be substituted); Ar<1> and Ar<2> are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; A is Y-(CH2)m-CH(R<2>)-(CH2)n-NR<1>-; R<1> is hydrogen, alkyl, benzyl or -(CH2)p-Y; R<2> is hydrogen, alkyl (which may be substituted), benzyl, 4-hydroxybenzyl, 3-indolylmethyl or -(CH2)p-Y; Y is -CN, -CH2Z or -COZ; Z is hydroxy, amino, alkoxy, alkylamino or dialkylamino; m, n and p are each, independently, 0, 1, 2 or 3; and R<1> and R<2> may be connected to form a ring.
Patent IL-107453-A0 (IL)
Title: Stable microbubble suspensions useful as enhancement agents for ultrasound echography
IPC: A61B8/08
Filed: 1993-11-01
Abstract: Disclosed are injectable suspensions of gas filled microbubbles in an aqueous carrier liquid usable as contrast agents in ultrasonic echography. The suspensions comprise amphipathic compounds of which at least one may be a laminarized phospholipid as a stabiliser of the microbubbles against collapse with time and pressure. The concentration of phospholipids in the carrier liquid is below 0.01% wt but is at least equal to or above that at which phospholipid molecules are present solely at the gas microbubble-liquid interface. Also disclosed is a method of preparation of the stable suspensions of air or gas filled microbubbles.
Patent IL-109562-A0 (IL)
Title: A process of recycling of disposable diapers and the machine components thereof
Inventor: CINA YARON
IPC: B29B17/04
Filed: 1994-05-05
Abstract: A process for recovering the cellulose flock component of used disposable sanitary non-woven cellulose articles (D), especially diapers (D) having also a plastics component and a superabsorbent polymer component, comprising: separating the cellulose flock component from the plastics component; disintegrating the cellulose flock component in water (14) into cellulose fibers and separating (18) them from the water (14) containing the super-absorbent polymer component and other waste, by selectively collecting the cellulose fibers onto a rough surface (18); disposing the water, effluent and separately compacting (19) the separated cellulose fibers and the separated plastics component prior to their discharge. The invention also provides an apparatus for carrying out the process.
Patent IL-113772-A0 (IL)
Title: Mucosal administration of pneumococcal antigens
IPC: A61P11/00
Filed: 1995-05-18
Abstract: Mucosal administration, particularly intranasally, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with cholera toxin B subunit, provides protection in animals against pneumococcal colonization and systemic infection. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Patent IL-129379-A0 (IL)
Title: Fibroblast growth factor homologs
IPC: C12N15/18
Filed: 1997-10-16
Abstract: There is provided an isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide selected from the group consisting of: a) a polynucleotide molecule comprising a nucleotide sequence as shown in SEQ ID. NO:1 from nucleotide 82 to nucleotide 621; b) allelic variants of (a); c) a polynucleotide molecule that encode a polypeptide that is at least 60% identical to the amino acid sequence of SEQ ID. NO:2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala); and d) a polynucleotide molecule comprising a nucleotide sequence as shown in SEQ ID. NO:6 from nucleotide 82 to nucleotide 621.
Patent IL-131912-A0 (IL)
Title: Process for preparing halogenated phenylmalonates
IPC: B01J27/122
Filed: 1999-09-15
Abstract: A process for the preparation of dialkyl phenylmalonates of formula I, <CHEM>  wherein R, R<1>, L<1> and L<2> have the meaning given in the claims,  which comprises  treating a phenylbromide of formula II <CHEM>  with a dialkyl malonate of formula III <CHEM>  in an inert solvent in the presence of a base and a copper salt, wherein 1.0 mole of the phenylbromide of formula II is treated with the enolate obtained from 2.0 to 4.0 moles of the dialkyl malonate of formula III and 2.0 to 3.8 moles of the base.
Patent IL-132702-A0 (IL)
Title: Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
IPC: A61P15/00
Filed: 1998-05-07
Abstract: This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.
Patent IL-142150-A0 (IL)
Title: New crystal modification iii of torasemide
IPC: A61P7/02
Filed: 1999-10-01
Abstract: New crystalline polymorph of torasemide, characterized by its powder x-ray diffraction pattern data; and its preparation by controlled acidification of alkaline torasemide solutions at specific temperatures and over specific periods. New crystal modification (form III) of torasemide, with spacings (d) between lattice planes, expressed in angstroms as 15.3898, 12.5973, 11.4565, 9.7973, 9.5493, 8.6802, 8.2371, 7.6351, 7.3356, 6.9759, 6.5351, 6.3240, 6.1985, 5.9521, 5.6237, 5.5623, 5.4040, 5.1119, 4.8738, 4.7865, 4.6986, 4.5985, 4.4602, 4.3405, 4.2552, 4.1829, 4.0768, 3.9377, 3.8659, 3.8429, 3.7801, 3.7248, 3.6239, 3.5556, 3.4825, 3.4130, 3.3055, 3.2298, 3.1786, 3.1278, 3.0699, 3.0078, 2.9549, 2.9056, 2.8541, 2.7686, 2.6988, 2.6610, 2.6293, 2.5549, 2.5236, 2.4485, 2.4161, 2.3671, 2.3133, 2.2788, 2.2312, 2.1852, 2.1468, 2.0957, 2.0617, 2.0273, 1.9896, 1.9688, 1.9274, 1.8853, 1.7931, 1.7449, 1.7169, 1.6512, 1.6122, 1.5601, 1.5320, 1.5057, 1.4521, and 1.3773. An independent claim is also included for the preparation of this new modification form III, by controlled acidification of an alkaline torasemide solution with inorganic or organic acids, with or without addition of a seed crystal, at a temperature of 0-35[deg]C within a period of 0.25-25 hours. ACTIVITY : Diuretic; cardiovascular; hypotensive; cardiant; ophthalmological; cytostatic; anticonvulsant; antiallergic; antiasthmatic. MECHANISM OF ACTION : None given.
Patent IL-143432-A0 (IL)
Title: Improvements in host computer access to peripheral device drivers
IPC: G06F13/10
Filed: 1999-11-23
Abstract: A peripheral device is cooperable with a host computer to direct the host computer to device information stored at an external location accessible to the host computer via an external data path. The device information can then be automatically downloaded to the host computer for use in conjunction with the peripheral device.
Patent IL-177213-A0 (IL)
Title: Apparatus and ,method for processing a multi-channel signal
IPC: G10L19/008
Filed: 2006-08-01
Abstract: An apparatus for processing a multi-channel signal includes a means for determining a similarity between a first one of two channels and a second one of the two channels. Furthermore, a means for performing a prediction filtering of the spectral coefficients is provided, which is formed to perform a prediction filtering with only a single prediction filter for both channels in case of high similarity between the first and the second channel, and to perform a prediction filtering with two separate prediction filters in case of a dissimilarity between the first and the second channel. With this, an introduction of stereo artifacts and a deterioration of the coding gain in stereo coding techniques are avoided.
Patent IL-182216-A0 (IL)
Title: Tantalum powder for the production of solid electrolyte capacitors
IPC: B22F1/00
Filed: 2007-03-27
Abstract: A tantalum powder consisting of agglomerated primary particle with a minimum primary particle dimension of 0.2 to 0.8 μm, a specific surface area of 0.9 to 2.5 m2/g and a particle size distribution determined to ASTM B 822 corresponding to a D10 value of 5 to 25 μm, a D50 value of 20 to 140 μm and a D90 value of 40 to 250 μm, wherein the powder does not comprise an effective content of sintering protection agents.
Patent IL-198012-A0 (IL)
Title: Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
Filed: 2009-04-05
Abstract: Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type TERT. TERT expression is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the TERT tumor-associated antigen, wherein aberrant TERT expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding TERT fusion proteins and TERT variants and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.